12.12.18 General

Advertisements

11 thoughts on “12.12.18 General”

  1. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

    Huimin Hu, Quanhua Mu, Zhaoshi Bao, Yiyun Chen, Yanwei Liu, Jing Chen, Kuanyu Wang, Zheng Wang, Yoonhee Nam, Biaobin Jiang, Jason K. Sa, Hee-Jin Cho, Nam-Gu Her, Chuanbao Zhang, Zheng Zhao, Ying Zhang, Fan Zeng, Fan Wu, Xun Kang, Yuqing Liu, Zenghui Qian, Zhiliang Wang, Ruoyu Huang, Qiangwei Wang, Wei Zhang, Xiaoguang Qiu, Wenbin Li, Do-Hyun Nam, Xiaolong Fan, Jiguang Wang, Tao Jiang

    https://www.cell.com/cell/fulltext/S0092-8674(18)31250-9

    Like

  2. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
    Haley E. Ramsey, Melissa A. Fischer…… Stephen W. Fesik and Michael R. Savona

    http://cancerdiscovery.aacrjournals.org/content/8/12/1566

    AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
    Sean Caenepeel, Sean P…… David C. Huang, Andrew Wei, Jude Canon, Angela Coxon and Paul E. Hughes

    http://cancerdiscovery.aacrjournals.org/content/8/12/1582

    Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer
    Varuna Nangia, Faria M. Siddiqui……Angela Coxon, Cyril H. Benes, Paul E. Hughes and Aaron N. Hata

    http://cancerdiscovery.aacrjournals.org/content/8/12/1598

    Liked by 1 person

  3. http://cancerdiscovery.aacrjournals.org/content/early/2018/11/28/2159-8290.CD-18-1151

    A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer

    Geoffrey J Lindeman, Sheau Wen Lok, James R Whittle, Francois Vaillant, Charis E. Teh, Louisa L Lo, Antonia N Policheni, Alice R. T. Bergin, Jayesh Desai, Sarah Ftouni, Luke C Gandolfo, Danny Liew, He K Liu, G. Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W. Roberts, Mark A Rosenthal, Kylie Shackleton, Maria J Silva, Zhen R Siow, Gordon K Smyth, Leanne Taylor, Avraham Travers, Belinda Yeo, Miriam M Yeung, Andjelija Zivanovic Bujak, Sarah-Jane Dawson, Daniel H. D. Gray and Jane E Visvader

    Like

  4. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
    Cancer Cell, ISSN: 1535-6108, Vol: 34, Issue: 6, Page: 879-891
    Publication Year: 2018
    https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30525-7

    A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
    Haley E. Ramsey, Melissa A. Fischer, Taekyu Lee, Agnieszka E. Gorska, Maria Pia Arrate, Londa Fuller, Kelli L. Boyd, Stephen A. Strickland, John Sensintaffar, Leah J. Hogdal, Gregory D. Ayers, Edward T. Olejniczak, Stephen W. Fesik and Michael R. Savona
    Cancer Discov December 1 2018 8 (12) 1566-1581; DOI:10.1158/2159-8290.CD-18-0140

    An identified MCL1 inhibitor induced apoptosis in AML cells and was safely combined with BCL2 inhibition to overcome BCL2 inhibitor resistance and enhance antitumor activity in mouse models of AML.

    AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
    Sean Caenepeel, Sean P. Brown, Brian Belmontes, Gordon Moody, Kathleen S. Keegan, Danny Chui, Douglas A. Whittington, Xin Huang, Leszek Poppe, Alan C. Cheng, Mario Cardozo, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A. Paras, Xianghong Wang, Joshua P. Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng Zhu, Elaina Cajulis, Tao Osgood, Jan Sun, Leah Damon, Regina K. Egan, Patricia Greninger, Joseph D. McClanaghan, Jianan Gong, Donia Moujalled, Giovanna Pomilio, Pedro Beltran, Cyril H. Benes, Andrew W. Roberts, David C. Huang, Andrew Wei, Jude Canon, Angela Coxon and Paul E. Hughes
    Cancer Discov December 1 2018 8 (12) 1582-1597; DOI:10.1158/2159-8290.CD-18-0387

    Drug discovery and optimization yielded the selective MCL1 inhibitor AMG 176, which induced apoptosis in cells from hematologic malignancies in vitro and in vivo and could be combined with other therapies.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s